<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623127</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-15-01</org_study_id>
    <nct_id>NCT02623127</nct_id>
  </id_info>
  <brief_title>A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma</brief_title>
  <acronym>KOSMIC</acronym>
  <official_title>A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the clinical activity of sunitinib in patients with advanced&#xD;
      thymic carcinoma who have failed chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sunitinib (Sutent®; Pfizer, New York, NY, USA) is a multitargeted tyrosine-kinase inhibitor&#xD;
      (TKI) with activity against the stem cell-factor receptor (KIT) and platelet-derived&#xD;
      growth-factor receptor (PDGFR), vascular endothelial growth-factor receptor (VEGFR), glial&#xD;
      cell line-derived neurotrophic factor receptor (rearranged during transfection [RET]),&#xD;
      colony-stimulating factor-1 receptor (CSF1R), and Fms-like tyrosine kinase-3 receptor (FLT3).&#xD;
&#xD;
      Sunitinib is a potent inhibitor of mutant KIT with additional inhibitory effects on VEGF&#xD;
      receptors that potentially might make it more effective than imatinib against TCs. In the&#xD;
      current version of NCCN guideline, sunitinib is suggested as one of the potential targeted&#xD;
      therapeutics for advanced TCs.&#xD;
&#xD;
      We planned this study to investigate the clinical efficacy and tolerability of sunitinib in&#xD;
      patients with advanced or recurrent TCs in Korean population. In addition, we will collect&#xD;
      tumor samples and blood samples from patients for the further exploration of predictive&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>CR or PR by RECIST criteria version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>CR or PR or SD by RECIST criteria version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From first day of study treatment to day of any kind of death, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related adverse events [Safety and Tolerability]</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of patients with adverse events during cycle 1 (each cycle is 21 days). Subjects will be evaluated for toxicity according to NCI-CTCAE(Common Terminology Criteria for Adverse Events) of version 4.0.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarker endpoint</measure>
    <time_frame>Day 1</time_frame>
    <description>When available, banked tumor tissue for genomic analysis for predictive biomarker of sunitinib.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed, written and dated informed consent prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          2. Histopathologically confirmed metastatic or recurrent thymic thymic carcinoma&#xD;
&#xD;
          3. Age ≥ 20&#xD;
&#xD;
          4. ECOG PS 0-2&#xD;
&#xD;
          5. Documented progressive disease after one or more conventional systemic chemotherapy&#xD;
&#xD;
          6. At least one measurable disease by RECIST v1.1&#xD;
&#xD;
          7. Adequate organ function for treatment as follows:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelets &gt;100 x 109/L&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0 x ULN (upper limit of normal)&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x ULN (without liver metastasis), ≤ 5.0 x ULN (with liver&#xD;
                  metastasis)&#xD;
&#xD;
          8. Life expectancy ≥ 12 weeks at day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with sunitinib or other VEGF-TKIs&#xD;
&#xD;
          2. Any major operation or irradiation within 4 weeks of baseline disease assessment&#xD;
&#xD;
          3. Any clinically significant gastrointestinal abnormalities which may impair intake or&#xD;
             absorption of the study drug&#xD;
&#xD;
          4. CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease&#xD;
             assessment (Asymptomatic CNS metastasis patients can be enrolled)&#xD;
&#xD;
          5. Patients with uncontrolled or significant cardiovascular disease (AMI within 12&#xD;
             months, Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure&#xD;
             or left ventricular ejection fraction below local institutional lower limit of normal&#xD;
             or below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia, Any&#xD;
             uncontrolled second or third degree heart block, Uncontrolled hypertension)&#xD;
&#xD;
          6. Concomitant malignancy (except adequately treated basal cell cancer of skin or&#xD;
             cervical cancer in situ)&#xD;
&#xD;
          7. Female patients who are pregnant, breast-feeding or male or female patients of&#xD;
             reproductive potential who are not employing an effective method of birth control&#xD;
&#xD;
          8. Other severe acute or chronic medical condition or laboratory abnormality that may&#xD;
             increase the risk associated with trial participation or investigational product&#xD;
             administration or may interfere with the interpretation of trial results and, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             trial. (including active bleeding, untreated DVT or thromboembolism)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Seok Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.jtho.2018.08.297</url>
    <description>Oral Presentation at WCLC 2018 (OA11.05 )</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Jong-Seok Lee</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Thymic carcinoma</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

